Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease

Vishnu C. Damalanka, Yunjeong Kim, Kevin R. Alliston, Pathum M. Weerawarna, Anushka C. Galasiti Kankanamalage, Gerald H. Lushington, Nurjahan Mehzabeen, Kevin P. Battaile, Scott Lovell, Kyeong Ok Chang, William C. Groutas

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Human noroviruses are the primary causative agents of acute gastroenteritis and a pressing public health burden worldwide. There are currently no vaccines or small molecule therapeutics available for the treatment or prophylaxis of norovirus infections. Norovirus 3CL protease plays a vital role in viral replication by generating structural and nonstructural proteins via the cleavage of the viral polyprotein. Thus, molecules that inhibit the viral protease may have potential therapeutic value. We describe herein the structure-based design, synthesis, and in vitro and cell-based evaluation of the first class of oxadiazole-based, permeable macrocyclic inhibitors of norovirus 3CL protease.

Original languageEnglish
Pages (from-to)1899-1913
Number of pages15
JournalJournal of Medicinal Chemistry
Volume59
Issue number5
DOIs
StatePublished - Mar 10 2016

Fingerprint

Dive into the research topics of 'Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease'. Together they form a unique fingerprint.

Cite this